| Effects of nitric oxide inhibition on basal forearm blood flow in patients with nonischemic chronic heart failure. | |
| | |
MedLine Citation:
|
PMID: 10328184 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Increased peripheral vascular tone in patients with chronic heart failure (CHF) is an important factor which contributes to increased cardiac afterload and reduced exercise capacity, and consequent further deterioration in CHF. The role of endogenous nitric oxide (NO) in the regulation of basal vascular tone in CHF is controversial. This study has investigated (1) whether basal NO bioavailability is reduced in the peripheral vasculature of patients with nonischemic CHF in the absence of confounding factors influencing endothelial function, and (2) if a difference is found, what clinical characteristics are related to the decreased NO-dependent vasodilation. Basal forearm blood flow (FBF) of 12 patients with CHF and 14 healthy volunteers was measured before and after administration of N(G)-monomethyl-L-arginine (L-NMMA) by venous occlusion plethysmography. After L-NMMA administration, basal FBF in both healthy subjects and patients with CHF decreased significantly, with the decrease in CHF patients being less than that in healthy volunteers (-0.7+/-0.2 vs -1.5+/-0.2 ml/min per 100 ml tissue, P < 0.01). When both groups were considered together, basal FBF was closely related to the decrease in FBF after L-NMMA administration (r = -0.83. P < 0.001). When CHF patients were divided into two groups according to NYHA class, the L-NMMA-induced decrease in FBF in moderate CHF (NYHA III; n = 7) was significantly less than that in mild CHF (NYHA II; n = 5) (-0.36+/-0.13 vs -1.16+/-0.72 ml/min per 100 ml tissue, P < 0.05). In conclusion, basal bioavailability of NO in the peripheral vascular bed in nonischemic CHF is impaired, with an increase in basal vascular tone and with progression of this disorder. This suggests that impaired basal NO bioactivity may make an important contribution to the elevated peripheral vascular tone and expression of symptoms seen in CHF. |
| | |
Authors:
|
H Yoshida; M Nakamura; T Akatsu; N Arakawa; K Hiramori |
Related Documents
:
|
21177844 - Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias. 6933324 - Attendance failure at paediatric medical outpatient clinics. 21373184 - The hla class ii allele drb1*1501 is over-represented in patients with idiopathic pulmo... 17521504 - Tips and tricks on outpatient initiation and uptitration of beta-blockade in heart fail... 8122534 - Soft cervical disc herniation: a retrospective study of 100 cases. 11014424 - Hyperthermia in the neurosurgical intensive care unit. |
Publication Detail:
|
Type: Comparative Study; Journal Article |
Journal Detail:
|
Title: Heart and vessels Volume: 13 ISSN: 0910-8327 ISO Abbreviation: Heart Vessels Publication Date: 1998 |
Date Detail:
|
Created Date: 1999-07-12 Completed Date: 1999-07-12 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8511258 Medline TA: Heart Vessels Country: JAPAN |
Other Details:
|
Languages: eng Pagination: 142-6 Citation Subset: IM |
Affiliation:
|
Second Department of Internal Medicine, Iwate Medical University, Morioka, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Blood Flow Velocity Enzyme Inhibitors / pharmacology Female Forearm / blood supply* Heart Failure / blood, drug therapy, physiopathology* Humans Infusions, Intra-Arterial Male Middle Aged Nitric Oxide / antagonists & inhibitors*, biosynthesis Nitric Oxide Synthase / antagonists & inhibitors* Reproducibility of Results Vascular Resistance omega-N-Methylarginine / pharmacology |
| Chemical | |
Reg. No./Substance:
|
0/Enzyme Inhibitors; 10102-43-9/Nitric Oxide; 17035-90-4/omega-N-Methylarginine; EC 1.14.13.39/Nitric Oxide Synthase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The hemodynamic impact of diffuse myocardial ischemic lesions: an animal experimental model based on...
Next Document: Reduced release of tissue factor by application of a centrifugal pump during cardiopulmonary bypass.